Medicine recall 27 May 2020

Company led drug alert – Duavive (conjugated oestrogen/bazedoxifene acetate) 0.45mg/20mg Modified Release Tablets – EU/1/14/960/001

Yes – this has been recalled
The problem
As a precautionary measure, Pfizer Limited is recalling the above batches from wholesalers due to out of specification results from the ongoing stability studies. An evaluation of the foil laminate pouch identified oxygen levels above the specified limits, resulting in lower dissolution results for bazedoxifene…
What to do
Check the batch number on your pack against the list below. Do not stop taking a prescribed medicine without talking to your pharmacist, GP or prescriber first – they can check your supply and swap it if needed.
Source: Medicines and Healthcare products Regulatory Agency (MHRA) Official notice ↗

CLDA Number

CLDA (20)A/02

MDR Number

MDR 142-05/20

Company Name

Pfizer Limited

Product Description

Duavive (conjugated oestrogen/bazedoxifene acetate)

0.45mg/20mg Modified Release Tablets – EU/1/14/960/001

Batch Number/Expiry

  • Batch number: AH1573
    • Expiry date: 08/2021
    • Pack size: 28 tablets
    • First distributed: 12/06/2019
  • Batch number: W96114
    • Expiry date: 09/2020
    • Pack size: 28 tablets
    • First distributed: 04/10/2018

Brief description of problem

As a precautionary measure, Pfizer Limited is recalling the above batches from wholesalers due to out of specification results from the ongoing stability studies. An evaluation of the foil laminate pouch identified oxygen levels above the specified limits, resulting in lower dissolution results for bazedoxifene acetate.

Company Contact for medical information enquiries

For medical information enquiries, please contact: Pfizer Medical Information

Tel: 01304 616161

Email: Medical.Information@pfizer.com

Company Contact for stock enquiries

Remaining stock of these batches should be quarantined and returned to Pfizer for credit.

For stock enquiries, please contact: Pfizer Customer Contact Centre

Tel: 0845 608 8866

Email: Customer.Services@Pfizer.com

Updated 27 May 2020. This page summarises an official notice. Details can change – always follow the official notice.

Website built by: www.NocturnalMedia.co.uk